Grifols, S.A. (VIE:GRF)

Market Cap	6.68B
Revenue (ttm)	7.52B
Net Income (ttm)	372.72M
Shares Out	n/a
EPS (ttm)	0.55
PE Ratio	17.92
Forward PE	10.56
Dividend	0.12 (1.13%)
Ex-Dividend Date	Aug 11, 2025

Volume	n/a
Average Volume	n/a
Open	11.05
Previous Close	10.91
Day's Range	11.01 - 11.10
52-Week Range	7.41 - 13.60
Beta	n/a
RSI	59.80
Earnings Date	Feb 25, 2026

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1909
• Employees: 23,833
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: GRF

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.